[Tolerance to celecoxib and meloxicam in patients with intolerance to nonsteroidal anti-inflammatory drugs].

S Vázquez-Cortés, L Vázquez-Fuertes, M Rodríguez-Alvarez, I Reig Rincón de Arellano, C Martínez-Cócera
{"title":"[Tolerance to celecoxib and meloxicam in patients with intolerance to nonsteroidal anti-inflammatory drugs].","authors":"S Vázquez-Cortés,&nbsp;L Vázquez-Fuertes,&nbsp;M Rodríguez-Alvarez,&nbsp;I Reig Rincón de Arellano,&nbsp;C Martínez-Cócera","doi":"10.4321/s0212-71992008000400003","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hypersensitive reactions to analgesics in the general population are less than 1%. Previous studies have demonstrated that cyclooxigenase 2 (COX-2) inhibitors are an efficient alternative in patients with non-steroidal anti-inflammatory drugs (NSAIDs) intolerance. The aim of our study is to test the tolerance to celecoxib and meloxicam in patients with NSAIDs intolerance, upto dosages higher than those used in previous studies.</p><p><strong>Material and methods: </strong>The subjects of the study were 38 NSAID-sensitive patients from September 2004 to June 2005. The diagnosis of intolerance to NSAIDs was carried out by means of single-blind placebo-controlled oral challenge with aspirin. We performed single-blind placebo controlled oral challenge tests with celecoxib (accumulated dose of 400 mg) and meloxicam (accumulated dose of 15 mg).</p><p><strong>Results: </strong>There was only one reaction with celecoxib (97.3%) which was generalised urticaria after the dose of 400 mg accumulated, it should be pointed out that this patient tolerated perfectly the dose of 200 mg. For meloxicam, we found 100% tolerance at a dosage of 15 mg, including the patient who showed a reaction to the celecoxib.</p><p><strong>Conclusion: </strong>We consider that there are patients with tolerance to low dosages of COX-2 inhibitors who show a reaction on increasing the administered dosage, which means that their tolerance should be taken into account and checked in the long term.</p>","PeriodicalId":50798,"journal":{"name":"Anales De Medicina Interna","volume":"25 4","pages":"163-7"},"PeriodicalIF":0.0000,"publicationDate":"2008-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De Medicina Interna","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4321/s0212-71992008000400003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

Introduction: Hypersensitive reactions to analgesics in the general population are less than 1%. Previous studies have demonstrated that cyclooxigenase 2 (COX-2) inhibitors are an efficient alternative in patients with non-steroidal anti-inflammatory drugs (NSAIDs) intolerance. The aim of our study is to test the tolerance to celecoxib and meloxicam in patients with NSAIDs intolerance, upto dosages higher than those used in previous studies.

Material and methods: The subjects of the study were 38 NSAID-sensitive patients from September 2004 to June 2005. The diagnosis of intolerance to NSAIDs was carried out by means of single-blind placebo-controlled oral challenge with aspirin. We performed single-blind placebo controlled oral challenge tests with celecoxib (accumulated dose of 400 mg) and meloxicam (accumulated dose of 15 mg).

Results: There was only one reaction with celecoxib (97.3%) which was generalised urticaria after the dose of 400 mg accumulated, it should be pointed out that this patient tolerated perfectly the dose of 200 mg. For meloxicam, we found 100% tolerance at a dosage of 15 mg, including the patient who showed a reaction to the celecoxib.

Conclusion: We consider that there are patients with tolerance to low dosages of COX-2 inhibitors who show a reaction on increasing the administered dosage, which means that their tolerance should be taken into account and checked in the long term.

[非甾体抗炎药不耐受患者对塞来昔布和美洛昔康的耐受性]。
简介:在一般人群中,对镇痛药的过敏反应不到1%。先前的研究表明,环氧化酶2 (COX-2)抑制剂是非甾体抗炎药(NSAIDs)不耐受患者的有效选择。本研究的目的是测试非甾体抗炎药不耐受患者对塞来昔布和美洛昔康的耐受性,最高剂量高于先前研究中使用的剂量。材料与方法:研究对象为2004年9月至2005年6月38例非甾体抗炎药敏感患者。对非甾体抗炎药不耐受的诊断是通过单盲安慰剂对照口服阿司匹林进行的。我们使用塞来昔布(累积剂量为400 mg)和美洛昔康(累积剂量为15 mg)进行了单盲安慰剂对照口服激发试验。结果:塞来昔布仅出现1例(97.3%)反应,累积剂量为400 mg后出现全局性荨麻疹,需要指出的是,该患者对200 mg剂量耐受良好。对于美洛昔康,我们发现15毫克剂量的耐受性为100%,包括对塞来昔布出现反应的患者。结论:我们认为存在对低剂量COX-2抑制剂耐受的患者,增加给药剂量后出现反应,应长期考虑并检查其耐受性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信